Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Objective: To establish whether savings could be made by changing patients from intramuscular to high doses of oral vitamin B12 in primary care without compromising their wellbeing. Methods: Cost-minimization analysis from a UK perspective, using secondary data obtained from the literature available and expert opinion. Results: The cost of the resources used to treat patients with vitamin B12 deficiency with intramuscular vitamin B12 was calculated as between £55.99 (€83.1) and £99.99 (€148.5) per year. The cost of treating patients with high doses of oral vitamin B12 during the first year was between £125.55 (€186.5) and £248.55 (€369.1). However, once patients receiving intramuscular treatment had been converted to oral treatment, or in new patients treated orally from the outset, the cost was £35.55 per year (€52.8). One variable, home visits, had a high impact on the calculations. Conclusion: Switching patients with vitamin B12 deficiency from intramuscular to high-dose oral therapy and treating patients newly diagnosed with vitamin B12 deficiency with oral vitamin B12 from the outset could save resources in the medium and long term, and in newly diagnosed patients. Savings would come particularly in the form of nursing time.

Original publication

DOI

10.1080/14017430601049449

Type

Journal

European Journal of General Practice

Publication Date

01/12/2006

Volume

12

Pages

169 - 173